Active Ingredient: Velaglucerase alfa
Velaglucerase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
60 - 60 [iU] per kg of body weight
From 60 To 60 [iU] per kg of body weight once every 14 day(s)
The recommended dose is 60 Units/kg administered every other week.
Dose adjustments can be made on an individual basis based on achievement and maintenance of therapeutic goals. Clinical studies have evaluated doses ranging from 15 to 60 Units/kg every other week. Doses higher than 60 Units/kg have not been studied.
Patients currently treated with imiglucerase enzyme replacement therapy for type 1 Gaucher disease may be switched to velaglucerase alfa, using the same dose and frequency.
To be administered as a 60-minute intravenous infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
